Import alerts, warning letters, drug recalls — why ‘pharmacy to the world’ is facing US FDA heat – ThePrint – Select
swifttelecast - 2024-04-23T05:38:03.000Z

Marksans, whose product portfolio includes therapeutic segments of cardiovascular, central nervous system, antidiabetic, pain management, gastroenterology and anti-allergy drugs and whose market capitalisation stood at Rs 5,299.75 crore in August last Read this story